Evidence map›Paper›PMID 32015267›Full record

ArticleJournal of the Chinese Medical Association : JCMA2020

The clinicopathological characteristics and genetic alterations of mucinous carcinoma of the stomach.

Chien-Hsun Tseng, Wen-Liang Fang, Kuo-Hung Huang, Ming-Huang Chen, Yee Chao, Su-Shun Lo, Anna Fen-Yau Li, Chew-Wun Wu, Yi-Ming Shyr

Open access · hybridAbstract read
In one paragraph

Article in Journal of the Chinese Medical Association : JCMA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Relationship betweenWorld journal of clinical oncology · 2025
    Article
  2. Article
  3. Review
  4. The role of cuproptosis in gastric cancer.Frontiers in immunology · 2024
    Review
  5. Comparison of Clinicopathological Features and Prognosis of Mucinous Gastric Carcinoma and other Gastric Cancers: A Retrospective Study of 4,417 Patients.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Mucinous gastric adenocarcinoma: A good candidate for immune therapy?Journal of the Chinese Medical Association : JCMA · 2020
    Article
  11. Annals of gastroenterology
    Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Chien-Hsun TsengDivision of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Wen-Liang FangDivision of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Kuo-Hung HuangDivision of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Ming-Huang ChenSchool of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.
Yee ChaoSchool of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.
Su-Shun LoSchool of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.
Anna Fen-Yau LiSchool of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.
Chew-Wun WuDivision of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Yi-Ming ShyrDivision of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Taipei Veterans General Hospital · TWNational Taipei University · TWNational Yang Ming Chiao Tung University · TWNational Yang Ming Chiao Tung University · TWNational Yang Ming University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMucinous gastric carcinoma (MGC) is rare and often associated with an advanced stage. The clinicopathological features and prognosis of MGC and non-MGC (NMGC) are controversial.

methodsIn total, 2637 gastric cancer (GC) patients receiving curative surgery were enrolled. The clinicopathological features and genetic alterations were compared between patients with MGC and NMGC.

resultsAmong the 2637 GC patients, 92 (3.5%) had MGC. After propensity score matching, compared to patients with NMGC, patients with MGC had more poorly differentiated tumors, medullary stromal reaction-type tumors, tumors with infiltrating Ming's classification, diffuse-type tumors, more abnormal preoperative serum carbohydrate antigen 19-9 levels, and more advanced T categories. After propensity score matching, there were no significant differences between MGC and NMGC regarding the initial recurrence patterns, 5-year overall survival (OS), and disease-free survival (DFS) rates. Multivariate analysis demonstrated that the MGC cell type is not an independent prognostic factor of OS and DFS. No significant differences in microsatellite instability status, Epstein-Barr virus infection, Helicobacter pylori infection, or genetic mutations were observed between MGC and NMGC. The expression of programmed death-ligand 1 (PD-L1) was significantly higher in MGC than that in NMGC. MGC was diagnosed at a more advanced stage compared with NMGC.

conclusionMGC itself was not an independent prognostic factor of worse survival. MGC was correlated with higher PD-L1 expression than NMGC, which may have a clinical impact on the treatment of MGC in the future.

Indexed as

MutationAdenocarcinoma, MucinousAdultAgedB7-H1 AntigenCA-19-9 AntigenCarcinoembryonic AntigenFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalPropensity ScoreProspective StudiesStomach NeoplasmsB7-H1 AntigenCA-19-9 AntigenCarcinoembryonic AntigenCD274 protein, human

Identifiers

PMID32015267
PMCPMC13047988
OpenAlexW3005467652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.